Last10K.com

Intermolecular Inc (IMI) SEC Filing 10-K Annual report for the fiscal year ending Monday, December 31, 2018

Intermolecular Inc

CIK: 1311241 Ticker: IMI

 

Exhibit 99.1

Intermolecular Reports Fourth Quarter and Full Year 2018 Financial Results

 

2018 Marked First Full Year of Positive Adjusted EBITDA Since 2013

Positive Operating Cash Flow of $5.9 million in 2018

 

SAN JOSE, Calif., February 12, 2019 -- Intermolecular, Inc. (Nasdaq: IMI),

the trusted partner for advanced materials innovation, today reported results for the fourth quarter and full year ended December 31, 2018.

 

Q4 2018 Financial and Operational Highlights

 

Revenue of $6.3 million, which exceeded the company’s guidance.

 

Program revenue totaled $6.0 million or 95% of total revenue.

 

Gross profit totaled $4.6 million or 73% of total revenue.

 

Adjusted EBITDA loss totaled $(1.5) million, which exceeded the company’s guidance.

 

Net loss totaled $(2.6) million.

 

Secured two program contracts during the period, including a major new program service agreement with a leading global semiconductor manufacturer. Management expects a material revenue contribution from this customer in 2019.

 

Full Year 2018 Financial and Operational Highlights

 

Revenue was $33.7 million.

 

Program revenue increased 10% to $32.0 million or 95% of total revenue.

 

Gross profit totaled $23.7 million or 70% of total revenue.

 

Total operating expenses decreased 22% to $28.0 million.

 

Adjusted EBITDA improved to $1.8 million compared to a loss of $(0.7) million in 2017.

 

Net loss improved to $(3.4) million compared to net loss of $(10.4) million in 2017.

 

Operating cash flow of $5.9 million in 2018.

 

Cash and investments at December 31, 2018 was $30.4 million (or $0.61 per share), an improvement from $25.8 million (or $0.52 per share) at the end of the prior fiscal year. The company continues to have no debt.

 

Management Commentary

“Our performance in 2018 reflected the successful execution of our plan – with $5.9 million of operating cash flow generated by the combination of strong performance with existing customers, commencement of major contracts with new customers, higher gross margins, a reduced cost structure and better working capital management,” said Intermolecular President and CEO Chris Kramer. “While we concluded certain programs to our customers’ satisfaction in 2018 which resulted in a short-term dip in our revenues that will continue in the first quarter of 2019, we retain excellent relationships with each of these customers, and we have secured major new customer programs that position us well for growth going forward.   

 

“We entered 2019 on solid footing with a strong balance sheet and a robust pipeline of business.  Following the major new customer we won in late 2018, we secured another contract with a new top tier leading global semiconductor company in the first quarter. With our lower cost structure and higher gross margins, our high throughput services platform now has strong operating leverage which will drive our profitability as we continue to scale our business.”

 

Fourth Quarter of 2018 Financial Results

Revenue for the fourth quarter of 2018 was $6.3 million, a decrease of 20% from $7.9 million in the third quarter of 2018, and a decrease of 40% from $10.6 million in the same period a year ago. Program revenue was $6.0 million, an 18% decrease from $7.4 million in the third quarter of 2018, and a 32% decrease from $8.9 million in the same period a year ago.

 


The following information was filed by Intermolecular Inc (IMI) on Tuesday, February 12, 2019 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Intermolecular Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Intermolecular Inc.

Continue

Assess how Intermolecular Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Intermolecular Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Financial
Revenue
Other
Filter Subcategory:
All
Expense
Earnings
Product
Income
Other
Inside Intermolecular Inc's 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Comprehensive Loss
Consolidated Statements Of Operations
Consolidated Statements Of Stockholders' Equity
Commitments And Contingencies
Commitments And Contingencies (Tables)
Commitments And Contingencies - Narrative (Details)
Commitments And Contingencies - Schedule Of Future Commitments And Obligations Under Operating Lease (Details)
Commitments And Contingencies - Schedule Of Rent Expense (Details)
Fair Value Of Financial Instruments
Fair Value Of Financial Instruments (Tables)
Fair Value Of Financial Instruments - Fair Value Of Cash Equivalents And Investments By Level Within Fair Value Hierarchy (Details)
Fair Value Of Financial Instruments - Narrative (Details)
Fair Value Of Financial Instruments - Schedule Of Cash, Cash Equivalents, And Investments (Details)
Income Taxes
Income Taxes (Tables)
Income Taxes - Components Of Provision For Annual Income Taxes (Details)
Income Taxes - Narrative (Details)
Income Taxes - Reconciliation Of Federal Statutory Income Tax To Provision For Income Taxes (Details)
Income Taxes - Significant Components Of Deferred Tax Assets And Liabilities (Details)
Income Taxes - Summary Of Activity Related To Unrecognized Tax Benefits (Details)
Information About Geographic Areas
Information About Geographic Areas (Tables)
Information About Geographic Areas - Schedule Of Revenue By Geographic Area (Details)
Intangible Assets
Intangible Assets (Tables)
Intangible Assets - Narrative (Details)
Intangible Assets - Schedule Of Finite-Lived Intangible Assets, Future Amortization Expense (Details)
Intangible Assets - Schedule Of Intangible Assets (Details)
Intangible Assets - Schedule Of Patent Amortization Expense (Details)
Net Loss Per Share Of Common Stock
Net Loss Per Share Of Common Stock (Tables)
Net Loss Per Share Of Common Stock - Schedule Of Antidilutive Potential Common Shares (Details)
Property And Equipment
Property And Equipment (Tables)
Property And Equipment - Narrative (Details)
Property And Equipment - Schedule Of Depreciation Expense (Details)
Property And Equipment - Schedule Of Property And Equipment (Details)
Related Party Transactions
Related Party Transactions (Tables)
Related Party Transactions - Narrative (Details)
Related Party Transactions - Schedule Of Related Party Revenue And Cost Of Revenue (Details)
Restructuring Charges
Restructuring Charges (Tables)
Restructuring Charges - Narrative (Details)
Restructuring Charges - Schedule Of Accrued Liabilities For Severance And Related Expenses And Payments (Details)
Stock-Based Compensation
Stock-Based Compensation (Tables)
Stock-Based Compensation - Narrative (Details)
Stock-Based Compensation - Schedule Of Assumptions For Fair Value Of Stock Options (Details)
Stock-Based Compensation - Schedule Of Grants Made By Entity (Details)
Stock-Based Compensation - Schedule Of Reserved Shares Of Common Stock (Details)
Stock-Based Compensation - Schedule Of Stock-Based Compensation Expense (Details)
Stock-Based Compensation - Schedule Of Stock-Based Compensation Expense, Net Of Estimated Forfeitures, By Grant Type (Details)
Stock-Based Compensation - Schedule Of Unrecognized Compensation Expense, Net Of Forfeitures, Expected To Be Recognized Over Weighted-Average Periods (Details)
Stock-Based Compensation - Summary Of Restricted Stock Award And Restricted Stock Unit (Rsus) Activity (Details)
Stock-Based Compensation - Summary Of Stock Option Activity (Details)
Stock-Based Compensation - Summary Of Stock Option Information By Exercise Price (Details)
Subsequent Event
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Tables)
Summary Of Significant Accounting Policies - Concentration Of Revenue And Accounts Receivable (Details)
Summary Of Significant Accounting Policies - Cumulative Effect Of Changes Made To Condensed Consolidated Balance Sheet For Adoption Of Asu (Details)
Summary Of Significant Accounting Policies - Impact Of Adoption Of Asc 606 On Condensed Consolidated Statement Of Operations And Balance Sheet (Details)
Summary Of Significant Accounting Policies - Narrative (Details)
Summary Of Significant Accounting Policies - Summary Of Contract Assets And Contract Liabilities From Contracts With Customers (Details)
Ticker: IMI
CIK: 1311241
Form Type: 10-K Annual Report
Accession Number: 0001564590-19-007009
Submitted to the SEC: Fri Mar 08 2019 11:21:43 AM EST
Accepted by the SEC: Fri Mar 08 2019
Period: Monday, December 31, 2018
Industry: Semiconductors And Related Devices

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/imi/0001564590-19-007009.htm